申请人:MERRELL DOW PHARMACEUTICALS INC.
公开号:EP0168813A1
公开(公告)日:1986-01-22
Sparsomycin derivatives of the formula
wherein X and y are each independently an oxo or an imino group; n ist 0 or the integer 1 or 2; R1 is a hydrogen or 1 to 4 carbon alkyl group; R2 is a hydrogen, a 1 to 4 carbon alkyl, a 2 to 5 carbon acyl or a benzoyl group; and R is a 1 to 6 carbon alkyl, 3 to 8 carbon alkenyl, cyanomethyl carboxymethyl, carbalkoxymethyl wherein the alkoxy moiety is a 1 to 4 carbon alkoxy group, nitromethyl, alkylcarbonylmethyl wherein the alkyl moiety is a 1 to 4 carbon alkyl group, pyri- dyi, furanyl, or furfuryl group or a phenyl or benzyl group optionally substituted by a methylendioxy or one to two halogen, 1 to 4 carbon alkyl, 1 to 4 carbon alkoxy, 1 to 4 carbon alkylthio, hydroxy, nitro or cyano groups or a pharmaceutically acceptable acid addition salt thereof. Also described are their use as antiprotozoals and antibacterials.
式中的 Sparsomycin 衍生物
其中 X 和 y 各自独立地为氧代或亚氨基;n 是 0 或整数 1 或 2;R1 是氢或 1 至 4 碳烷基;R2 是氢、1 至 4 碳烷基、2 至 5 碳酰基或苯甲酰基;R2 是氢或 1 至 4 碳烷基、2 至 5 碳酰基或苯甲酰基;R1 是氢或 1 至 4 碳烷基、2 至 5 碳酰基或苯甲酰基;R2 是氢或 1 至 4 碳烷基、2 至 5 碳酰基或苯甲酰基;R1 是氢或 1 至 4 碳烷基、2 至 5 碳酰基或苯甲酰基;R2 是氢或 1 至 4 碳烷基、2 至 5 碳酰基或苯甲酰基、或呋喃基,或苯基或苄基,可选择被甲硫基或一至两个卤素、1 至 4 碳烷基、1 至 4 碳烷氧基、1 至 4 碳烷硫基、羟基、硝基或氰基取代,或其药学上可接受的酸加成盐。此外,还介绍了它们作为抗原虫剂和抗菌剂的用途。